secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001062993-25-016864
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix
------------------------------------------------------------------------------

- Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.
- Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.
- Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).
- Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.
- Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/0001062993-25-016864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-016864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer